{"prompt": "['Event', 'Action to Be Taken', 'Hypersensitivity', 'Suspected cases should be fully evaluated and treated as', 'clinically indicated.', 'Medicinal products for the treatment of hypersensitivity', 'reactions (e.g., epinephrine, antihistamines, and', 'glucocorticoids) and resuscitation equipment must be available', 'for immediate use during the initial administrations of', 'emicizumab in the infusion center, clinic, or hospital.', 'If a patient has symptoms of anaphylaxis or severe', 'hypersensitivity, administration of emicizumab must be', 'immediately stopped and treatment of the reaction must be', 'initiated.', 'The investigator should contact the Medical Monitor to assess if', 'the clinical benefit clearly outweighs the risk, to determine if and', 'when the patient should resume taking emicizumab, and', \"discuss the patient's continued study participation. If patient\", 'continues in the study, the next two scheduled doses must be in', 'a monitored setting with at least a 60-minute observation period', 'and resuscitation treatment immediately available. After each of', 'these two doses in the clinic, the site will call the patient', '24 hours after each dose to assess the status of the patient.', 'Investigators may order any pertinent laboratory tests, including', 'an unscheduled ADA evaluation, in the event that any of these', 'reactions occur.', 'Hypercoagulation and risk', 'Investigators should be vigilant for patients who exhibit', 'of thrombosis', 'signs/symptoms consistent with thrombotic disease and should', 'immediately begin work up and treatment as per local', 'guidelines.', 'If a patient has a thromboembolic event, further administration', 'of emicizumab should be interrupted. The investigator must', 'contact the Medical Monitor to assess if the clinical benefit', 'clearly outweighs the risk to determine if the patient should', \"resume taking emicizumab and discuss the patient's continued\", 'study participation.', 'Please see Sections 0 and 0.9 for guidance on the management', 'of breakthrough bleeds, including required laboratory', 'monitoring.', 'TMA', 'Investigators should be vigilant for patients who exhibit', 'signs/symptoms consistent with TMA and immediately begin', 'work-up and treatment, as per local guidelines.', 'If a patient has a TMA event, further administration of', 'emicizumab should be interrupted. The decision to resume taking', 'emicizumab after a TMA event must be discussed with and', 'approved by the Medical Monitor.', 'Please see Sections 0 and 0.9 for guidance on the management', 'of breakthrough bleeds, including required laboratory', 'monitoring.', 'ADA=anti-drug antibody; TMA=thrombotic microangiopathy', 'Emicizumab - F. Hoffmann-La Roche Ltd', '129 / Protocol MO39129, Version 3']['5.1.3', 'Interpretation of Coagulation Assays for Patients Receiving', 'Emicizumab', 'Emicizumab interacts with standard laboratory assays used in the management of patients', 'with hemophilia A (see Table 11). In one-stage assays, emicizumab is associated with a', 'supra-physiologically short time to clot formation and thus normalization of aPTT at', 'sub-therapeutic levels. Emicizumab is not recognized or neutralized by FVIII inhibitors, and', 'therefore FVIII inhibitors cannot be detected in the presence of emicizumab by functional tests', 'such as Bethesda or Nijmegen-Bethesda assays, which use a one-stage clotting-based', 'readout. Emicizumab activity cannot be detected by chromogenic assays using purified', 'bovine coagulation proteins, thus chromogenic Bethesda assays using bovine proteins can be used', 'to measure FVIII inhibitor titer in the presence of emicizumab. Emicizumab activity can be', \"detected using chromogenic assays composed of human proteins. See the Investigator's\", 'Brochure for additional details on which tests can be used and how the test results can be', 'interpreted.', 'Table 12', 'Coagulation Test Results Affected and Unaffected by Emicizumab', 'Results Affected by Emicizumab', 'Results Unaffected by Emicizumab', 'aPTT', 'Bethesda assays (bovine chromogenic) for FVIII', 'Bethesda assays (clotting-based) for FVIII inhibitor', 'inhibitor titers', 'titers', 'Thrombin time', 'One-stage, aPTT-based, single-factor assays', 'One-stage, prothrombin time-based, single-factor', 'aPTT-based Activated Protein C Resistance', 'assays', 'Activated clotting time', 'Chromogenic-based single-factor assays other than', 'FVIII [a]', 'Immuno-based assays (i.e., ELISA, turbidimetric', 'methods)', 'Genetic tests of coagulation factors (e.g., Factor V', 'Leiden, Prothrombin 20210)', 'ELISA = enzyme-linked immunosorbent assay', 'a.', 'For important considerations regarding FVIII chromogenic activity assays, see Drug Interactions listed in', 'the us Package Insert', '5.2', 'SAFETY PARAMETERS AND DEFINITIONS', 'Safety assessments will consist of monitoring and recording adverse events, including', 'serious adverse events and adverse events of special interest, performing protocol-specified', 'safety laboratory assessments, measuring protocol-specified vital signs, and conducting', 'other protocol-specified tests that are deemed critical to the safety evaluation of the study.', 'Certain types of events require immediate reporting to the Sponsor, as outlined in Section 0.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '130 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}